Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology company that became publicly traded in September 2021 through a de-SPAC merger with Soaring Eagle Acquisition Corp, a blank-check vehicle sponsored by Eagle Equity Partners LLC, whose principals included veteran SPAC sponsors Harry Sloan and Jeff Sagansky. The company operates in the biotechnology and cell-programming sector, offering a platform for engineering organisms across pharmaceuticals, agriculture, and industrial applications. On August 5, 2026, Ginkgo Bioworks filed an 8-K current report with the SEC under accession number 0001628280-26-053319, disclosing a material event to investors. Visit SpacDesk and sign up for full data, filing analytics, and real-time alerts on Ginkgo Bioworks and hundreds of other de-SPAC companies.